Every earnings call for LAURUSLABS — management tone, guidance, KPIs and promise tracking, quarter by quarter.
LAURUSLABS · 6 transcripts · Healthcare · latest Q4 FY26Laurus Labs has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue (FY26) ₹6,813 cr (+23% YoY); EBITDA (FY26) ₹1,826 cr; EBITDA Margin (FY26) 26.8% (+7% YoY). Revenue of ₹6,813 crores, up 23% YoY for FY26.
Read full transcript & analysisRevenue ₹1,778 cr (+26% YoY); EBITDA ₹485 cr; EBITDA Margin 27.0%. Q3 FY26 Revenue stood at ₹1,778 crores, with 9M FY26 revenue at ₹5,001 crores, up 30% YoY.
Read full transcript & analysisEBITDA (Q3) ₹485 cr; EBITDA Margin (Q3) 27%; Profit After Tax (Q3) ₹252 cr. Q3 Revenue of ₹1,778 crores, up 26% YoY.
Read full transcript & analysisEBITDA (Q2) ₹429 cr; EBITDA Margin (Q2) 26%; PAT (Q2) ₹195 cr. Revenue of ₹1,653 crores, up 35% YoY.
Read full transcript & analysisRevenue ₹1,570 cr (+31% YoY); EBITDA ₹389 cr; EBITDA Margin 25%. Revenue of ₹1,570 crores, up 31% YoY.
Read full transcript & analysisEBITDA (Q4) ₹477 cr; EBITDA Margin (Q4) 27.7%; PAT (Q4) ₹234 cr. Q4 FY25 Revenue of ₹1,720 crores, up 19% YoY.
Read full transcript & analysis